Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$16.74
-1.4%
$14.02
$9.57
$30.41
$2.31B0.961.53 million shs1.65 million shs
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$53.07
+3.2%
$45.01
$1.16
$14.10
$2.30B-0.12189,291 shs359,190 shs
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
$30.22
+1.5%
$24.80
$17.38
$30.69
$2.21B0.06508,646 shs702,152 shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$14.69
+1.1%
$14.02
$2.80
$8.97
$529.69M0.6337,931 shs545,433 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-1.36%0.00%+19.83%+11.08%-32.06%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
+3.21%+11.96%+19.96%-1.59%+33.61%
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
+1.51%+4.64%+12.59%+36.37%+61.09%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
+1.10%+1.10%+9.30%+19.33%+63.77%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
3.7269 of 5 stars
3.42.00.03.42.42.50.0
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
3.0142 of 5 stars
3.52.00.00.03.13.30.6
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2.75
Moderate Buy$43.71161.14% Upside
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
0.00
N/AN/AN/A
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
3.00
Buy$38.8028.39% Upside
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SBTX, ARWR, GMTX, and KNSA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
5/13/2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$21.00 ➝ $17.00
5/13/2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
4/29/2025
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$40.00 ➝ $45.00
4/16/2025
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.00
3/13/2025
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$40.00
(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$545.21M4.24N/AN/A$1.54 per share10.87
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/A$2.89 per shareN/A
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
$481.17M4.58N/AN/A$6.23 per share4.85
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/A$7.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$599.49M-$1.40N/AN/AN/AN/A-236.60%-64.09%8/6/2025 (Estimated)
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/A
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
$14.08M-$0.25N/A120.88N/A-2.36%-7.31%-5.95%7/22/2025 (Estimated)
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-$89.48M-$2.42N/AN/AN/A-29.62%-28.20%N/A

Latest SBTX, ARWR, GMTX, and KNSA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q2 2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$0.06$2.75+$2.81$2.75$116.27 million$542.71 million
4/29/2025Q1 2025
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
$0.02$0.11+$0.09$0.11$128.35 million$137.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
N/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
7.27
6.09
6.09
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/A
71.49
71.49
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
N/A
3.24
2.95
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/A
67.87
67.87
CompanyEmployeesShares OutstandingFree FloatOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
400138.10 million120.68 millionOptionable
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
3043.33 million37.74 millionNot Optionable
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
22072.97 million32.80 millionOptionable
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
8336.06 million23.65 millionNot Optionable

Recent News About These Companies

10 Fun Facts About Mountain Gorillas
ARS Pharmaceuticals Inc (SPRY)
Wild Isles
A look back at RNA Therapeutics – day one
SPRY ARS Pharmaceuticals, Inc.
FDA accepts ARS Pharma’s NDA for Neffy
INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT
SBTX Silverback Therapeutics, Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arrowhead Pharmaceuticals stock logo

Arrowhead Pharmaceuticals NASDAQ:ARWR

$16.74 -0.23 (-1.36%)
Closing price 06/11/2025 04:00 PM Eastern
Extended Trading
$16.96 +0.22 (+1.34%)
As of 06/11/2025 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Gemini Therapeutics stock logo

Gemini Therapeutics NASDAQ:GMTX

$53.07 +1.65 (+3.21%)
As of 06/10/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Kiniksa Pharmaceuticals stock logo

Kiniksa Pharmaceuticals NASDAQ:KNSA

$30.22 +0.45 (+1.51%)
Closing price 06/11/2025 04:00 PM Eastern
Extended Trading
$30.23 +0.01 (+0.03%)
As of 06/11/2025 05:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Silverback Therapeutics stock logo

Silverback Therapeutics NASDAQ:SBTX

$14.69 +0.16 (+1.10%)
As of 06/10/2025

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.